DeCure for Leukodystrophy, hypomyelinating, 19, transient infantile
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for leukodystrophy, hypomyelinating, 19, transient infantile — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLeukodystrophy, hypomyelinating, 19, transient infantile maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for leukodystrophy, hypomyelinating, 19, transient infantile is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transmembrane protein 63A (TMEM63A) — TMEM63A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8GRS · 3.3 Å · ligand (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate (POV). Experimental structure, not a prediction.
What the evidence adds up to
The three abstracts provided contain almost no information about treatment or drug repurposing for hypomyelinating leukodystrophy, including the 19 transient infantile variant. The 2023 review describes genetic mutations that cause protein misfolding, dysfunction, or mislocalisation in HLDs, and states that understanding these pathways can provide new findings for clinical treatments, but it gives no specific drug, trial, or outcome data. The 2023 case report describes an infant with HLD-13 diagnosed by next-generation sequencing showing a pathogenic homozygous variant, but it reports no treatment, no drug, and no survival or response numbers. The 2009 abstract concerns Wnt13 isoforms in bovine aortic endothelial cells and is entirely irrelevant to leukodystrophy.
No concrete numbers on survival, response rates, or sample sizes appear in any of these abstracts. No drug is mentioned in connection with HLD. There is no evidence of efficacy, no trial results, and no suggestion that any compound has been tested in this patient population. The abstracts are limited to genetic characterisation and general statements about future therapeutic possibilities.
What is missing is any clinical trial data, any tested drug, any patient stratification strategy, and any funding for treatment studies specific to transient infantile hypomyelinating leukodystrophy. Without these, no drug repurposing can be assessed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology International · 2023 · 15 citations · open access
Molecular Pathogenic Mechanisms of Hypomyelinating Leukodystrophies (HLDs)
AbstractHypomyelinating leukodystrophies (HLDs) represent a group of congenital rare diseases for which the responsible genes have been identified in recent studies. In this review, we briefly describe the genetic/molecular mechanisms underlying the pathogenesis of HLD and the normal cellular functions of the related genes and proteins. An increasing number of studies have reported genetic mutations that cause protein misfolding, protein dysfunction, and/or mislocalization associated with HLD. Insight into the mechanisms of these pathways can provide new findings for the clinical treatments of HLD.
A Rare Case of Hypomyelinating Leukodystrophy and Its Management: A Case Report and Literature Review
AbstractA subset of hereditary white matter disorders called hypomyelinating leukodystrophies (HLD) is characterized primarily by the absence of myelin deposition. Although the clinical presentation can be mild and the development of symptoms can occur in adolescence or adulthood, the majority of severe cases present during infancy and early childhood with significant neurological impairments. The clinical features vary from muscle stiffness to seizures and developmental delay. The detailed myelination process can be seen with magnetic resonance imaging (MRI), and many patients are diagnosed using MRI pattern recognition and next-generation sequencing (NGS) in most cases. Here, we report a case of an infant suffering from the hypomyelinating leukodystrophy-13 (HLD-13) variant, whose next-generation sequencing revealed a pathogenic homozygous variant.
Neurology International · 2009 · 0 citations · open access
The interplay between the expression and functions of Wnt13 isoforms during apoptosis in bovine aortic endothelial cells
AbstractHypomyelinating leukodystrophies (HLDs) represent a group of congenital rare diseases for which the responsible genes have been identified in recent studies. In this review, we briefly describe the genetic/molecular mechanisms underlying the pathogenesis of HLD and the normal cellular functions of the related genes and proteins. An increasing number of studies have reported genetic mutations that cause protein misfolding, protein dysfunction, and/or mislocalization associated with HLD. Insight into the mechanisms of these pathways can provide new findings for the clinical treatments of HLD.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
